Sleep Apnoea Patients Face 71% Higher Risk of Cardiovascular Events and Mortality
Individuals suffering from obstructive sleep apnoea (OSA) may be at a dramatically increased risk of death or major cardiovascular problems compared to those without the breathing disorder, according to groundbreaking new research. The study reveals that people with OSA could be 71 per cent more likely to experience life-threatening events such as heart attacks and strokes, or to die from any cause.
Alarming Statistics from UK Health Records Analysis
Researchers from Imperial College Health Partners conducted an extensive analysis of health records involving more than 20,000 adults in north-west London diagnosed with OSA, comparing them with approximately 100,000 individuals without the condition. Over a four-year study period, the findings were stark: around 26 per cent of people with OSA experienced a cardiovascular event or died, compared with just 17.5 per cent of those without the breathing disorder.
Even after accounting for confounding factors including smoking habits and pre-existing health conditions, the research team identified a 71 per cent higher overall risk of cardiovascular events or death among OSA patients. This elevated risk persisted despite similar obesity levels observed in both study groups.
The Obesity Connection and Growing Prevalence
With excess weight established as the leading cause of obstructive sleep apnoea, medical experts emphasize that these findings "underscore the need for effective obesity management" according to researchers preparing to present their results at the European Congress on Obesity in Turkey next month.
The Sleep Apnoea Trust estimates that approximately 10 million people in the United Kingdom may currently be living with OSA, the most common type of sleep apnoea characterized by repeated breathing interruptions during sleep. Disturbingly, projections indicate this number will increase substantially in coming decades.
Heather Fitzke, co-author of the study from Imperial College Health Partners, stated: "In adults, obstructive sleep apnea is linked to higher risk of cardiovascular events or all-cause mortality, especially among those with obesity, even after adjusting for confounders. These findings underscore the need for effective obesity management and highlight the importance of early screening and timely diagnosis."
Recognizing Symptoms and Associated Health Conditions
The NHS identifies several key symptoms of obstructive sleep apnoea including:
- Loud, persistent snoring
- Gasping, snorting or choking noises during sleep
- Frequent nighttime awakenings
- Excessive daytime fatigue
Beyond cardiovascular risks, the study also found that individuals with OSA were more likely to develop additional health conditions including diabetes, osteoarthritis, and anxiety disorders. The condition can cause sufferers to wake up to 40 times per night, frequently with a sudden snort or gasp as breathing resumes.
Treatment Options and Management Strategies
Primary treatment for obstructive sleep apnoea typically involves using a continuous positive airway pressure (CPAP) machine, which employs a mask to maintain open airways during sleep. However, healthcare professionals emphasize that lifestyle modifications play a crucial role in managing the condition.
The NHS recommends several key approaches for OSA management:
- Weight loss through diet and regular exercise
- Establishing consistent sleep routines
- Creating optimal sleep environments (dark, quiet bedrooms)
- Sleeping on one's side rather than back
- Avoiding alcohol and quitting smoking
- Using sleeping pills only under medical supervision
Serious Complications of Untreated Sleep Apnoea
Left untreated, obstructive sleep apnoea can lead to numerous serious health complications including:
- High blood pressure and hypertension
- Type 2 diabetes development
- Depression and mood disorders
- Increased accident risk due to persistent fatigue
- Concentration difficulties and cognitive impairment
The condition also increases the likelihood of entering hypoxic states characterized by dangerously low blood oxygen levels. While the brain typically wakes sleeping individuals during these episodes, repeated hypoxia can damage brain cells, impair judgment, and cause memory problems.
It is noteworthy that the study revealing these significant findings was sponsored by pharmaceutical company Lilly, manufacturer of obesity and diabetes medications including Mounjaro. Researchers describe their work as "the largest matched case-control study of obstructive sleep apnea outside the U.S. to date," providing compelling evidence for enhanced screening and intervention strategies across the United Kingdom's healthcare system.
